{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:12:28Z","timestamp":1792465948191,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40268-025-00511-y","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:20:55Z","timestamp":1748424055000},"page":"161-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-6506","authenticated-orcid":false,"given":"Sarah","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-8776","authenticated-orcid":false,"given":"Meaghan","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1850-9855","authenticated-orcid":false,"given":"Elizabeth M.","family":"Salvo-Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maebh","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gavata-Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-5422","authenticated-orcid":false,"given":"Ingo","family":"Pragst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelanjana","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-8055","authenticated-orcid":false,"given":"Imtiaz A.","family":"Samjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"511_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fmed.2018.00022","volume":"5","author":"WR Lumry","year":"2018","unstructured":"Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease. Front Med (Lausanne). 2018;5:22.","journal-title":"Front Med (Lausanne)."},{"issue":"14 Suppl.","key":"511_CR2","first-page":"S292","volume":"24","author":"J Bernstein","year":"2018","unstructured":"Bernstein J. Severity of hereditary angioedema, prevalence, and diagnostic considerations. AM J Manag Care. 2018;24(14 Suppl.):S292\u20138.","journal-title":"AM J Manag Care"},{"issue":"1","key":"511_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00403-024-03652-3","volume":"317","author":"A Raja","year":"2025","unstructured":"Raja A, Shuja MH, Raja S, Qammar A, Kumar S, Khurram L, et al. Efficacy and safety of donidalorsen in hereditary angioedema with C1 inhibitor deficiency: a systematic review and a meta analysis. Arch Dermatol Res. 2025;317(1):110.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"511_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18176\/jiaci.0653","volume":"31","author":"T Caballero","year":"2021","unstructured":"Caballero T. Treatment of hereditary angioedema. J Investig Allergol Clin Immunol. 2021;31(1):1\u201316.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"511_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"511_CR6","unstructured":"EMA. Takhzyro: EPAR: product information. 2024."},{"key":"511_CR7","unstructured":"US FDA. Takhzyro (lanadelumab-flyo): label. 2022."},{"key":"511_CR8","unstructured":"Health Canada. Summary basis of decision: Takhzyro. Health Canada [updated February 18, 2019]. https:\/\/hpr-rps.hres.ca\/reg-content\/summary-basis-decision-detailTwo.php?linkID=SBD00420#:~:text=To%20ensure%20safe%20and%20effective,acute%20treatment%20of%20HAE%20attacks. Accessed 13 May 2025."},{"key":"511_CR9","unstructured":"TGA. Australian public assessment report for lanadelumab [updated March 2020]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-lanadelumab-200304.pdf. Accessed 13 May 2025."},{"key":"511_CR10","unstructured":"US FDA. Package insert: Haegarda. 2020."},{"key":"511_CR11","unstructured":"EMA. Assessment report: Orladeyo. 2021."},{"key":"511_CR12","unstructured":"US FDA. Package onsert: Orladeyo. 2020."},{"key":"511_CR13","unstructured":"CSL Behring. CSL Behring presents results for garadacimab as preventive treatment in hereditary angioedema [updated June 8, 2020]. https:\/\/www.cslbehring.com\/newsroom\/2020\/eaaci-2020-garadacimab-data. Accessed 13 May 2025."},{"key":"511_CR14","unstructured":"EMA. Andembry garadacimab EMEA\/H\/C\/006116 authorisation details. 2025."},{"issue":"5","key":"511_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades A, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607\u201317.","journal-title":"Med Decis Mak"},{"key":"511_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"511_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"511_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"511_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647.","journal-title":"BMJ"},{"issue":"2","key":"511_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods."},{"issue":"4","key":"511_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health."},{"issue":"4","key":"511_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health."},{"key":"511_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JP Jansen","year":"2013","unstructured":"Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.","journal-title":"BMC Med"},{"issue":"2","key":"511_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"511_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1214\/20-BA1221","volume":"16","author":"A Vehtari","year":"2021","unstructured":"Vehtari A, Gelman A, Simpson D, Carpenter B, B\u00fcrkner P-C. Rank-normalization, folding, and localization: an improved R for assessing convergence of MCMC (with discussion). Bayesian Anal. 2021;16(2):667\u2013718.","journal-title":"Bayesian Anal"},{"key":"511_CR26","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 13 May 2025."},{"issue":"3","key":"511_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","volume":"125","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Schwartz L, Yang W, Baker J, Anderson J, Farkas H, et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2020;125(3):334-40.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"511_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1089\/ped.2020.1143","volume":"33","author":"D Levy","year":"2020","unstructured":"Levy D, Caballero T, Hussain I, Reshef A, Anderson J, Baker J, et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2020;33(3):136\u201341.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"3","key":"511_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100882","volume":"17","author":"D Honda","year":"2024","unstructured":"Honda D, Hide M, Fukuda T, Koga K, Morita E, Moriwaki S, et al. Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: parts 2 and 3 of the randomized APeX-J phase III trial. World Allergy Org J. 2024;17(3): 100882.","journal-title":"World Allergy Org J."},{"issue":"6","key":"511_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/all.14670","volume":"76","author":"I Ohsawa","year":"2021","unstructured":"Ohsawa I, Honda D, Suzuki Y, Fukuda T, Kohga K, Morita E, et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy. 2021;76(6):1789\u201399.","journal-title":"Allergy"},{"issue":"10328","key":"511_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","volume":"399","author":"T Craig","year":"2022","unstructured":"Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399(10328):945\u201355.","journal-title":"Lancet"},{"issue":"6","key":"511_CR32","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2352-3026(24)00081-4","volume":"11","author":"TJ Craig","year":"2024","unstructured":"Craig TJ, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, et al. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. Lancet Haematol. 2024;11(6):e436\u20137.","journal-title":"Lancet Haematol."},{"issue":"10382","key":"511_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10382):1079\u201390.","journal-title":"Lancet"},{"issue":"20","key":"511_CR34","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108\u201321.","journal-title":"JAMA"},{"key":"511_CR35","unstructured":"Berotralstat (BCX7353); Study BCX7353-302: Part 1 Interim Clinical Study Report, (October 31, 2019). 2019."},{"issue":"1","key":"511_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12955-019-1229-3","volume":"17","author":"K Kulthanan","year":"2019","unstructured":"Kulthanan K, Chularojanamontri L, Rujitharanawong C, Weerasubpong P, Maurer M, Weller K. Angioedema quality of life questionnaire (AE-QoL): interpretability and sensitivity to change. Health Qual Life Outcomes. 2019;17(1):160.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"511_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40268-021-00337-4","volume":"21","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Malmenas M, Haeussler K, Hunger M, Jain G, Devercelli G. Indirect comparison of lanadelumab and intravenous C1-INH using data from the HELP and CHANGE studies: Bayesian and Frequentist analyses. Drugs R D. 2021;21(1):113\u201321.","journal-title":"Drugs R D."},{"issue":"6","key":"511_CR38","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0188","volume":"12","author":"M Watt","year":"2023","unstructured":"Watt M, Malmenas M, Romanus D, Haeussler K. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema. J Comp Eff Res. 2023;12(6): e220188.","journal-title":"J Comp Eff Res."},{"issue":"11","key":"511_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"12","key":"511_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","volume":"376","author":"H Longhurst","year":"2017","unstructured":"Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131\u201340.","journal-title":"N Engl J Med"},{"issue":"5","key":"511_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2500\/aap.2018.39.4164","volume":"39","author":"HH Li","year":"2018","unstructured":"Li HH, Mycroft S, Christiansen S, Wood DN, Feuersenger H, Pawaskar D, et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy Asthma Proc. 2018;39(5):365\u201370.","journal-title":"Allergy Asthma Proc"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00511-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00511-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:31Z","timestamp":1750694131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00511-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00511-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by CSL Behring. The authors have received no other financial and\/or material support for this research or the creation of this work apart from that disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John Sears, Yinglei Li, Iris Jacobs, and Neelanjana Ray are employees of CSL Behring, USA. Maebh Kelly is an employee of CSL Behring Ltd. Simona Gavata-Steiger and Chiara Nenci are employees of CSL Behring AG. Ingo Pragst is an employee of CSL Innovation GmbH, Germany. Sarah Walsh, Meaghan Bartlett, Elizabeth M. Salvo-Halloran, and Imtiaz A. Samjoo are employees of EVERSANA, Canada, which was a paid consultant to CSL Behring in connection with the development of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Openly available data that support the findings of this study are available within the paper and its supplementary information. Data that are not openly available are available upon reasonable request in accordance with the internal CSL Behring data sharing policy.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in the conception and design of the study. SW, MB, EH, and IAS contributed to the collection and analysis of the data. All authors contributed to the interpretation of the data and critically reviewed for the importance of intellectual content for the work. All authors were responsible for drafting or reviewing the manuscript and for providing final approval. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}